CBD prevented morphine-induced pain hypersensitivity and partially reduced withdrawal in rats

In rats made physically dependent on morphine (10 days of twice-daily treatment), repeated CBD (30 mg/kg) prevented thermal hyperalgesia in both males and females. When withdrawal was induced with naloxone, morphine-dependent female rats predominantly showed rearing behavior while males showed teeth chattering. CBD treatment on day 11 partially attenuated withdrawal behavior in males, with milder effects in females (only in high withdrawal responders).

Male and female rats underwent morphine-induced physical dependence protocol (7.89 mg/kg twice daily for 10 days). Nociception measured with hot plate test. Naloxone-precipitated withdrawal behavior scored after 11 days. CBD (30 mg/kg) tested for effects on both hyperalgesia and withdrawal.

Opioid use disorder involves both tolerance-related hyperalgesia and withdrawal symptoms, and current treatments have significant limitations. Finding that CBD can prevent opioid-induced hyperalgesia while partially managing withdrawal symptoms opens a potential complementary treatment pathway.

The opioid crisis demands alternatives for managing both pain and opioid side effects. These findings suggest CBD could complement opioid therapy by preventing the pain hypersensitivity that develops with chronic opioid use, potentially reducing the need for dose escalation.

Animal study that may not translate to human opioid dependence. Single CBD dose tested. Withdrawal attenuation was partial, not complete. Sex differences in response complicate translation. Naloxone-precipitated withdrawal differs from spontaneous withdrawal.